# UK Protein Therapeutics Market > UK Protein Therapeutics Market Research Report: Size, Share, Trend Analysis By Types (Monoclonal Antibodies, Insulin, Fusion Protein, Erythropoietin, Interferon), By Applications (Cancer, Metabolic Disorders, Immunologic Disorders, Hematological Disorders) and By End Users (Hospitals and Clinics, Specialty Centers) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.39% - **2024:** $ 8.35 Billion - **2025:** $ 8.88 Billion - **2035:** $ 16.5 Billion - **Key Players:** Amgen (US), Genentech (US), AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly (US), Sanofi (FR), Novo Nordisk (DK), Regeneron Pharmaceuticals (US), Merck & Co. (US) **Report ID:** MRFR/LS/50028-HCR · **Pages:** 200 · **Author:** Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/uk-protein-therapeutics-market-51786 --- ## Market Summary ## **UK Protein Therapeutics Market Overview** As per MRFR analysis, the UK Protein Therapeutics Market Size was estimated at 11.45 (USD Billion) in 2023. The UK Protein Therapeutics Market Industry is expected to grow from 12.24(USD Billion) in 2024 to 24.88 (USD Billion) by 2035. The UK Protein Therapeutics Market CAGR (growth rate) is expected to be around 6.661% during the forecast period (2025 - 2035). **Key UK Protein Therapeutics Market Trends Highlighted** The UK Protein Therapeutics Market is experiencing significant growth driven by a surge in healthcare investments and advancements in biopharmaceutical research. The focus on personalized medicine is shaping the market, as therapies tailored to the individual's genetic makeup are becoming more prevalent. Research institutions and pharmaceutical companies in the UK are increasingly collaborating to innovate protein-based drugs, which are showing effective results in treating various chronic conditions.  The demand for monoclonal antibodies and biologics has seen a notable increase, reflecting ongoing trends toward more targeted and efficient therapies. In the UK market, there are numerous opportunities for exploration, particularly in the areas of regulatory support and funding for innovative therapeutics. The United Kingdom government is committed to cultivating an environment that is conducive to biotechnology innovation. The significance of health technologies is underscored by initiatives like the Life Sciences Industrial Strategy, which establishes a strong foundation for the advancement of novel protein therapeutics.  This presents an opportunity for emerging companies to increase their research and development efforts by utilising governmental support. In recent years, there has been a significant transition to the development of environmentally benign and sustainable production methods for protein therapeutics. The UK market is currently experiencing a surge in interest in biomanufacturing methods that optimise productivity and reduce carbon footprints.  Additionally, the rapid development of more effective therapeutics is being facilitated by the rapid advancements in technologies such as CRISPR and recombinant DNA, which is consistent with the increasing trend of incorporating cutting-edge technology into drug discovery. In general, these trends underscore the dynamic nature of the UK Protein Therapeutics Market and its alignment with broader healthcare objectives. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **UK Protein Therapeutics Market Drivers** **Growing Incidence of Chronic Diseases** The increasing prevalence of chronic diseases, such as diabetes, cancer, and autoimmune disorders, is a significant driver for the UK Protein Therapeutics Market Industry. According to the National Health Service (NHS), there has been a notable rise in the number of diabetes cases, with over 4.9 million people currently diagnosed in the UK. This represents a 10% increase over the last five years. With a growing aging population, the demand for innovative protein therapeutics that target these chronic conditions is anticipated to rise significantly. Established organizations like AstraZeneca and GlaxoSmithKline are actively involved in Research and Development of targeted therapies that cater to these diseases, further propelling market growth in the UK. Their advancements in therapeutic solutions highlight the importance of protein-based treatments, which are crucial in managing chronic diseases and improving patient outcomes. **Advancements in Biopharmaceuticals** Technological innovations in biopharmaceuticals, especially in the production of protein therapeutics, are driving significant growth in the UK Protein Therapeutics Market Industry. Recent advancements in biotechnology and gene editing technologies, such as CRISPR, have streamlined the design and manufacturing processes of biologics. According to the UK BioIndustry Association, the UK biopharmaceutical sector has grown by 9% annually, leading to a surge in new therapies developed using sophisticated protein engineering methods. Companies like Biogen and Cambridge Antibody Technology are at the forefront of these advancements, contributing to the increasing availability of innovative protein-based treatments. This growth trajectory showcases the potential of therapeutic proteins in addressing unmet medical needs, continuing to shape the future of healthcare in the UK. **Increasing Investment in Biotechnology** Investment in biotechnology is rapidly increasing, providing a substantial boost to the UK Protein Therapeutics Market Industry. The UK government has committed to investing in life sciences through the Life Sciences Vision, which aims to attract 1 billion in research and innovation funding. This strategic move is designed to enhance the UK's position as a global leader in life sciences and biopharmaceuticals.  According to the UK Research and Innovation agency, the biotechnology sector is predicted to contribute 63 billion to the UK's economy by 2025.This influx of investment allows companies like Johnson & Johnson and Sanofi to accelerate their Research and Development processes, fostering the creation of new protein therapeutics that can address various diseases more effectively. The combination of governmental support and private sector investment plays a crucial role in stimulating growth and expansion in the UK Protein Therapeutics Market. **UK Protein Therapeutics Market Segment Insights** **Protein Therapeutics Market Type Insights** The UK Protein Therapeutics Market is characterized by its diverse range of categories, each playing a significant role in advancing healthcare solutions. Among these categories, Monoclonal Antibodies have gained considerable prominence due to their targeted therapeutic properties, making them essential in treating various chronic diseases, including cancers and autoimmune disorders. This segment demonstrates a high level of innovation and research investment, leading to a consistent supply of novel therapies that address specific patient needs.Insulin remains a cornerstone of diabetes management, with advancements in formulations and delivery methods contributing to improved patient outcomes.  The demand for insulin therapies showcases the critical role proteins play in regulating health, especially as the prevalence of diabetes continues to rise within the UK. Fusion Proteins represent another vital category that combines the benefits of different proteins to enhance therapeutic efficacy and reduce side effects, thereby providing diverse treatment options for patients facing complex health challenges. Erythropoietin is crucial for preventing and treating anemia, particularly in patients with chronic kidney disease or those undergoing chemotherapy, emphasizing the importance of targeted protein therapies in managing specific medical conditions. Interferon, known for its antiviral and immunomodulatory effects, has been instrumental in treating conditions such as hepatitis and multiple sclerosis, reinforcing the role of this protein class in infectious disease management.  Together, these segments underscore the dynamic landscape of the UK Protein Therapeutics Market, driven by continuous innovation and a growing commitment to addressing unmet healthcare needs while improving patient quality of life.Through extensive Research and Development, the market showcases resilience and adaptability amidst evolving healthcare challenges, positioning itself for future growth opportunities. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Protein Therapeutics Market Application Insights** The Application segment of the UK Protein Therapeutics Market plays a crucial role in addressing diverse health concerns prevalent in the region, particularly through categories such as Cancer, Metabolic Disorders, Immunologic Disorders, and Hematological Disorders. Cancer treatment remains a key focus area, as innovative protein therapeutics enhance efficacy and reduce side effects compared to traditional therapies, reflecting significant advancements in targeted treatment methodologies.  Similarly, the metabolic disorders category is gaining prominence, spurred by rising obesity rates and related health issues, necessitating specific protein solutions that can effectively manage these conditions.The importance of immunologic disorders cannot be overstated, especially considering the growing need for effective therapies amid increasing incidences of autoimmune diseases. Meanwhile, hematological disorders receive dedicated attention owing to the escalating demand for better treatment options for blood-related ailments.  As noted by health authorities, the robust growth in these therapeutic areas indicates a combined effort to improve patient outcomes and enhance the overall quality of life. By leveraging advancements in biopharmaceutical research, the UK aims to bolster its position within the global Protein Therapeutics Market industry while addressing these critical health challenges through effective therapeutic applications. **Protein Therapeutics Market End User Insights** The UK Protein Therapeutics Market is significantly influenced by its End User segment, which comprises key entities such as Hospitals and Clinics, as well as Specialty Centers. Hospitals and Clinics serve as primary healthcare providers where protein therapeutics are crucial for treating various conditions, particularly in oncology, immunology, and hematology. These establishments frequently adopt advanced therapeutic solutions, thus playing a vital role in driving the demand for protein-based treatments. Specialty Centers, focusing on specific therapeutic areas, allow for tailored treatment plans, ensuring that patients receive the most appropriate therapeutics for their conditions.The growing prevalence of chronic diseases and the increasing focus on personalized medicine in the UK are expected to enhance the significance of these End Users.  Additionally, advancements in technologies and drug development continue to support the evolution of the UK Protein Therapeutics Market landscape. As the healthcare industry in the UK prioritizes improved patient outcomes, the contribution of these End Users to the overall market growth remains notable, positioning them as crucial players in the therapeutic domain. With evolving healthcare policies and a robust regulatory framework, the opportunities within this segment are poised to expand, aligning with the overarching trends in the industry. **UK Protein Therapeutics Market Key Players and Competitive Insights** The UK Protein Therapeutics Market is characterized by a complex landscape with a number of key players vying for dominance. The market is driven by significant advancements in biopharmaceutical technologies, increasing investments in research and development, and the growth of personalized medicine initiatives. Competitive insights reveal that companies in this sector are focusing on innovation, enhancing their product pipelines, and adopting strategies to strengthen their market position.  With increasing demand for protein therapeutics, driven by rising incidences of chronic diseases and an aging population, organizations are leveraging their expertise in biotechnology to deliver effective treatments. The competitive dynamics are influenced by factors such as regulatory frameworks, market access strategies, collaboration among stakeholders, and geographical expansion.Johnson & Johnson has established a strong foothold in the UK Protein Therapeutics Market, building on its extensive experience in the pharmaceutical sector. The company's strength lies in its broad portfolio of innovative therapies, particularly in immunology and oncology, which have been well-received in the UK healthcare system.  Johnson & Johnson's commitment to research and development has enabled it to bring forth cutting-edge treatments that address unmet medical needs, capturing the interest of healthcare providers and patients alike. Furthermore, the company has leveraged strong relationships with healthcare professionals, institutions, and payers to ensure the successful adoption of its products in clinical settings. In terms of regulatory compliance, Johnson & Johnson has demonstrated a robust ability to navigate the complex landscape, which further enhances its competitive stance. GlaxoSmithKline operates as a significant contributor in the UK Protein Therapeutics Market, focusing on developing and marketing a range of biologic therapies. The company’s strengths lie in its substantial investment in R&D, particularly for vaccines and specialty medicines that tackle urgent health challenges in the UK. Key products from GlaxoSmithKline include monoclonal antibodies and other biologics that have shown promising results across various therapeutic areas. The company's established presence and strong market share are further bolstered by strategic collaborations and partnerships aimed at enhancing therapeutic offerings.  GlaxoSmithKline's commitment to innovation is exemplified by its recent mergers and acquisitions that expand its capabilities and diversify its product pipeline. This strategic positioning allows GlaxoSmithKline to meet the evolving healthcare demands in the UK, making it a prominent player in the protein therapeutics domain. **Key Companies in the UK Protein Therapeutics Market Include:** **UK Protein Therapeutics Market Industry Developments** Recent developments in the UK Protein Therapeutics Market have been marked by significant activity among major companies. Johnson and Johnson continues to advance their pipeline of protein therapeutics, particularly focusing on oncology treatments. GlaxoSmithKline has made strides in biopharmaceutical collaborations aimed at enhancing their protein therapeutics portfolio.  Merck is also actively contributing to advancements in immunotherapy. In terms of mergers and acquisitions, it was reported in October 2022 that GlaxoSmithKline acquired the biotechnology firm Affinivax, which specializes in developing protein-based vaccines, marking a notable expansion in the protein therapeutics domain. Meanwhile, Eli Lilly announced in September 2023 the acquisition of a peptide drug development company to bolster their immunology and oncology segments.  Growth in the market has been reflected in increased valuations for key players, driven by innovation and rising investments in Research and Development. Over the past few years, collaborations have intensified, such as the partnership between AstraZeneca and Regeneron Pharmaceuticals in mid-2021 to develop monoclonal antibodies, showcasing the competitive landscape that characterizes the UK Protein Therapeutics Market. **UK Protein Therapeutics Market Segmentation Insights** **Protein Therapeutics Market Type Outlook** **Protein Therapeutics Market Application Outlook** **Protein Therapeutics Market End User Outlook** - Hospitals and Clinics ## Market Drivers ### Growing Focus on Rare Diseases The protein therapeutics market is increasingly focusing on the treatment of rare diseases, which often lack effective therapies. In the UK, the prevalence of rare diseases is estimated to affect approximately 1 in 17 individuals, creating a substantial unmet medical need. This has prompted pharmaceutical companies to invest in the development of protein therapeutics specifically targeting these conditions. The UK government has introduced incentives for the development of orphan drugs, which may further stimulate interest in this segment of the market. As awareness of rare diseases grows, The market is likely to see an expansion in product offerings., catering to this niche yet critical area of healthcare. ### Increasing Demand for Biologics The protein therapeutics market is experiencing a notable surge in demand for biologics, driven by their efficacy in treating chronic diseases. In the UK, the biologics segment is projected to account for approximately 30% of the overall pharmaceutical market by 2026. This growth is attributed to the increasing prevalence of conditions such as cancer, autoimmune disorders, and diabetes, which require advanced therapeutic solutions. The shift towards biologics is further supported by healthcare providers and patients seeking more effective treatment options, thereby propelling the protein therapeutics market forward. Additionally, the UK government has been investing in research and development initiatives aimed at enhancing the production and accessibility of biologics, which may further stimulate market growth. ### Regulatory Support and Innovation The protein therapeutics market benefits from a robust regulatory framework in the UK, which encourages innovation and expedites the approval process for new therapies. The Medicines and Healthcare products Regulatory Agency (MHRA) has implemented streamlined pathways for biologics, allowing for faster market entry of novel protein therapeutics. This regulatory support is crucial, as it fosters an environment conducive to research and development, enabling companies to bring innovative solutions to market more efficiently. Furthermore, the UK government has introduced various funding schemes aimed at supporting biotech firms, which may enhance the competitive landscape of the protein therapeutics market. As a result, the market is likely to witness an influx of new products, catering to diverse therapeutic needs. ### Rising Investment in Biotechnology Investment in biotechnology is witnessing a significant increase in the UK, which is positively impacting the protein therapeutics market. Venture capital funding for biotech firms has surged, with estimates indicating a growth of over 40% in the last two years. This influx of capital is enabling companies to invest in research and development, leading to the discovery of novel protein therapeutics. Additionally, collaborations between academic institutions and industry players are fostering innovation, further driving the market. The UK government has also been proactive in supporting biotech initiatives, which may enhance the overall ecosystem for protein therapeutics. As a result, the market is likely to expand, with a diverse range of therapeutic options becoming available. ### Technological Advancements in Drug Development Technological advancements are playing a pivotal role in shaping the protein therapeutics market. Innovations in areas such as gene editing, protein engineering, and high-throughput screening are enhancing the efficiency of drug development processes. In the UK, the integration of artificial intelligence and machine learning in drug discovery is expected to reduce development timelines by up to 30%, thereby accelerating the introduction of new protein therapeutics. These advancements not only improve the likelihood of successful outcomes but also reduce costs associated with drug development. Consequently, the protein therapeutics market is poised for growth as companies leverage these technologies to create more effective and targeted therapies. ## Future Outlook The [Protein Therapeutics Market](https://www.marketresearchfuture.com/reports/protein-therapeutics-market-10142) is projected to grow at 6.39% CAGR from 2025 to 2035, driven by advancements in biotechnology, increasing chronic disease prevalence, and rising demand for personalized medicine. **New opportunities:** - Development of biosimilars to enhance market access and affordability. - Investment in AI-driven drug discovery platforms to expedite therapeutic development. - Expansion of cold chain logistics for improved distribution of temperature-sensitive products. By 2035, the protein therapeutics market is expected to achieve substantial growth, driven by innovation and strategic investments. ## Segment Insights ### By Type: Monoclonal Antibodies (Largest) vs. Vaccines (Fastest-Growing) The UK protein therapeutics market showcases a diverse distribution of segment values, with monoclonal antibodies holding the largest market share. This segment is characterized by its widespread applications in treating various diseases, leading to significant stakeholder investments. In contrast, vaccines represent the fastest-growing segment, driven by advancements in technology and increasing public health initiatives. Growth trends indicate a robust future for both segments. Monoclonal antibodies are experiencing consistent demand due to their therapeutic efficacy, particularly in oncology and autoimmune diseases. Meanwhile, the vaccines segment is dynamically expanding, fueled by heightened public awareness and accelerated vaccine development efforts, particularly in the wake of global health crises. This growth reflects an overall surge in biopharmaceutical innovations and consumer health focus. Monoclonal Antibodies (Dominant) vs. Vaccines (Emerging) Monoclonal antibodies are considered the dominant players in the UK protein therapeutics market, widely recognized for their specificity and efficacy in targeting diseases such as cancer and rheumatoid arthritis. With a well-established manufacturing and distribution framework, this segment attracts significant research and development funding, ensuring a continuous pipeline of innovative therapies. On the other hand, vaccines are emerging as a crucial segment, particularly in the context of recent global health challenges. The emphasis on preventive healthcare and government initiatives to promote vaccination is driving growth in this area. Vaccines are becoming more sophisticated, leveraging new technologies such as mRNA, and addressing a broader spectrum of infectious diseases, enhancing their market potential. ### By Application: Oncology (Largest) vs. Autoimmune Diseases (Fastest-Growing) In the UK protein therapeutics market, the distribution of market share among application segments reveals that oncology leads significantly, capturing a large portion of overall revenues. This dominance is driven by high prevalence rates and the continuous innovation in cancer therapies. Conversely, autoimmune diseases represent the fastest-growing segment, thanks to increased awareness and diagnosis, resulting in a rising demand for targeted therapies. The growth trends indicate that the oncology segment, while dominant, is facing fierce competition and the growing demand for multi-targeted therapies. On the other hand, the autoimmune diseases segment is benefiting from advancements in biologics and personalized medicine. This trend is expected to persist as healthcare providers increasingly focus on tailored treatment options, leveraging protein therapeutics to improve patient outcomes. Oncology (Dominant) vs. Autoimmune Diseases (Emerging) The oncology segment stands out as the dominant force in the UK protein therapeutics market, largely due to the increasing incidence of various cancers and significant investments in research and development. Oncology therapies often include monoclonal antibodies and targeted therapies, which have revolutionized treatment protocols. In contrast, the autoimmune diseases segment is emerging rapidly, spurred by novel therapeutic agents and enhanced diagnostic capabilities. Conditions like rheumatoid arthritis and multiple sclerosis are gaining focus, with therapies tailored to specific patient profiles. This burgeoning interest underscores the need for effective treatment solutions and showcases the potential for innovative protein therapeutics to meet this demand. ### By End Use: Hospital (Largest) vs. Research Laboratories (Fastest-Growing) In the UK protein therapeutics market, hospitals account for the largest share, as they are the pivotal institutions where these therapies are administered to patients. Their significant role in patient care drives the demand for therapeutic proteins, leading to increased investment and focus on this segment. Research laboratories also play a crucial role, often serving as incubators for innovation, contributing to the overall market dynamics with their growing involvement in therapeutic development. Growth trends within the end-use segment indicate a robust expansion trajectory for both hospitals and research laboratories. Hospitals continue to innovate in patient treatment protocols, enhancing their therapeutic offerings, while research laboratories are rapidly evolving to support the demands of the biotechnology industry. The exploration of new protein therapeutics is spurred by advancements in technology and an increasing focus on personalized medicine, positioning research laboratories as the fastest-growing end-use segment, catering to the surge in biopharmaceutical research. Hospital (Dominant) vs. Research Laboratories (Emerging) Hospitals represent the dominant end-use segment in the UK protein therapeutics market, leveraging their infrastructure and resources to provide therapeutic proteins to a wide patient demographic. The integration of protein therapeutics into standardized treatment protocols further cements their essential position. Conversely, research laboratories are emerging as critical players, fueling innovation and development of new protein therapeutics. These laboratories are characterized by their agile approach, often collaborating with pharmaceutical companies to fast-track research initiatives. As personalized medicine gains traction, the role of research laboratories becomes increasingly significant, enabling the transition from laboratory findings to clinical applications effectively. ### By Mode of Administration: Intravenous (Largest) vs. Subcutaneous (Fastest-Growing) In the UK protein therapeutics market, the mode of administration has a diverse distribution among key segments. Intravenous administration currently represents the largest share due to its established efficacy and widespread acceptance in clinical settings. On the other hand, subcutaneous administration is gaining traction, appealing for its convenience and comfort in self-administration, which is becoming increasingly popular among patients. Intramuscular administration, while still relevant, is lagging behind the other two in terms of market share and growth. Growth trends indicate a shift towards more patient-centric approaches, which is driving the demand for subcutaneous products. Advances in formulation technologies are facilitating the development of innovative therapeutics that can be administered subcutaneously, thus expanding this segment's share in the market. Meanwhile, intravenous administration remains a staple for more acute treatments and complex diseases. The evolving landscape is prompting pharmaceutical companies to adapt their strategies to stay competitive in this dynamic segment. Subcutaneous (Dominant) vs. Intramuscular (Emerging) The subcutaneous mode of administration is becoming increasingly dominant in the UK protein therapeutics market due to its advantages over traditional routes. It allows for self-administration, reducing the need for clinical visits, which is particularly beneficial for chronic conditions requiring regular treatment. Patients favor subcutaneous therapies for their reduced discomfort and enhanced mobility. Intramuscular administration, while still used, is seen as an emerging method with limited appeal primarily in specific therapeutic areas. Its slower market growth compared to subcutaneous options is due to factors such as increased patient preference for non-invasive delivery methods and advancements in drug delivery technologies that favor the development of subcutaneous formulations. ## Competitive Benchmarking The protein therapeutics market is characterized by a dynamic competitive landscape, driven by innovation, strategic partnerships, and a focus on addressing unmet medical needs. Key players such as Amgen (US), AbbVie (US), and Sanofi (FR) are actively shaping the market through their distinct operational strategies. Amgen (US) emphasizes innovation in biologics, particularly in oncology and cardiovascular diseases, while AbbVie (US) leverages its strong portfolio in immunology and oncology to maintain a competitive edge. Sanofi (FR), on the other hand, is focusing on expanding its presence in rare diseases and gene therapies, indicating a strategic shift towards high-value therapeutics. Collectively, these strategies contribute to a competitive environment that is increasingly focused on specialized treatments and patient-centric solutions.In terms of business tactics, companies are increasingly localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The competitive structure of the market appears moderately fragmented, with several key players holding substantial market shares while also facing competition from emerging biotech firms. This fragmentation allows for a diverse range of therapeutic options, although the influence of major players remains significant in shaping market trends and standards. In October Amgen (US) announced a strategic partnership with a leading AI firm to enhance its drug discovery processes. This collaboration aims to leverage artificial intelligence to streamline the identification of potential therapeutic candidates, thereby accelerating the development timeline. The strategic importance of this move lies in Amgen's commitment to integrating cutting-edge technology into its operations, which could potentially lead to more efficient and effective drug development. In September AbbVie (US) completed the acquisition of a biotech company specializing in gene therapy, which is expected to bolster its capabilities in this rapidly evolving field. This acquisition not only expands AbbVie's portfolio but also positions the company to capitalize on the growing demand for gene-based treatments. The strategic significance of this action reflects AbbVie's intent to diversify its offerings and enhance its competitive positioning in the market. In August Sanofi (FR) launched a new initiative aimed at increasing access to its protein therapeutics in underserved regions. This initiative includes partnerships with local healthcare providers and investments in infrastructure to improve distribution channels. The strategic importance of this move underscores Sanofi's commitment to addressing The protein therapeutics market reach. As of November current competitive trends in the protein therapeutics market are increasingly defined by digitalization, sustainability, and the integration of AI technologies. Strategic alliances are playing a crucial role in shaping the landscape, enabling companies to pool resources and expertise to drive innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on technological advancements, innovative therapies, and reliable supply chains. This shift suggests that companies that prioritize innovation and operational excellence will be better positioned to thrive in the future. ## Recent News & Developments Recent developments in the UK Protein Therapeutics Market have been marked by significant activity among major companies. Johnson and Johnson continues to advance their pipeline of protein therapeutics, particularly focusing on oncology treatments. GlaxoSmithKline has made strides in biopharmaceutical collaborations aimed at enhancing their protein therapeutics portfolio.  Merck is also actively contributing to advancements in immunotherapy. In terms of mergers and acquisitions, it was reported in October 2022 that GlaxoSmithKline acquired the biotechnology firm Affinivax, which specializes in developing protein-based vaccines, marking a notable expansion in the protein therapeutics domain. Meanwhile, Eli Lilly announced in September 2023 the acquisition of a peptide drug development company to bolster their immunology and oncology segments.  Growth in the market has been reflected in increased valuations for key players, driven by innovation and rising investments in Research and Development. Over the past few years, collaborations have intensified, such as the partnership between AstraZeneca and Regeneron Pharmaceuticals in mid-2021 to develop monoclonal antibodies, showcasing the competitive landscape that characterizes the UK Protein Therapeutics Market. ## Report Scope | MARKET SIZE 2024 | 8.35(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 8.88(USD Billion) | | MARKET SIZE 2035 | 16.5(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.39% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Amgen (US), Genentech (US), AbbVie (US), Bristol-Myers Squibb (US), Eli Lilly (US), Sanofi (FR), Novo Nordisk (DK), Regeneron Pharmaceuticals (US), Merck & Co. (US) | | Segments Covered | Type, Application, End Use, Mode of Administration | | Key Market Opportunities | Advancements in biologics manufacturing technologies enhance efficiency in the protein therapeutics market. | | Key Market Dynamics | Rising demand for innovative protein therapeutics drives competitive dynamics and regulatory adaptations in the UK market. | | Countries Covered | UK | ## Frequently Asked Questions **Q: What was the market valuation of the UK protein therapeutics market in 2024?** A: The market valuation was $8.35 Billion in 2024. **Q: What is the projected market valuation for the UK protein therapeutics market by 2035?** A: The projected valuation for 2035 is $16.5 Billion. **Q: What is the expected CAGR for the UK protein therapeutics market during the forecast period 2025 - 2035?** A: The expected CAGR during this period is 6.39%. **Q: Which segment of the UK protein therapeutics market had the highest valuation in 2024?** A: Monoclonal Antibodies had the highest valuation at $3.35 Billion in 2024. **Q: What is the projected valuation for Recombinant Proteins by 2035?** A: The projected valuation for Recombinant Proteins is $5.0 Billion by 2035. **Q: Which application segment is expected to grow the most in the UK protein therapeutics market?** A: Metabolic Disorders is expected to grow the most, with a projected valuation of $6.35 Billion by 2035. **Q: What was the valuation of the Hospital end-use segment in 2024?** A: The Hospital end-use segment was valued at $2.5 Billion in 2024. **Q: What is the projected valuation for the Pharmaceutical Companies end-use segment by 2035?** A: The projected valuation for Pharmaceutical Companies is $7.5 Billion by 2035. **Q: Which mode of administration segment had the highest valuation in 2024?** A: The Subcutaneous mode of administration had the highest valuation at $3.0 Billion in 2024. **Q: What is the projected valuation for the Intramuscular mode of administration by 2035?** A: The projected valuation for the Intramuscular mode of administration is $5.5 Billion by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/uk-protein-therapeutics-market-51786*